Results 131 to 140 of about 16,802 (217)

Comparison of the Hemagglutination Inhibition Test and IgG ELISA in Categorizing Primary and Secondary Dengue Infections Based on the Plaque Reduction Neutralization Test. [PDF]

Biomed Res Int, 2016
Lukman N, Salim G, Kosasih H, Susanto NH, Parwati I, Fitri S, Alisjahbana B, Widjaja S, Williams M.   +8 more
europepmc   +1 more source

From Fragments to Function: Novel Hydrazone Derivatives as Monoamine Oxidase Inhibitors

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
Twelve N‐acylhydrazone derivatives (5a–f, 6a–f) were synthesized and characterized. Compounds displayed potent submicromolar inhibition against both MAO‐A and MAO‐B. Compound 6e exhibited the strongest activity (IC50 = 0.073 μM for MAO‐A; 0.064 μM for MAO‐B). Kinetic and docking analyses confirmed reversible, competitive inhibition via FAD interaction.
Hasan Erdinç Sellitepe, Ahmet Buğra Aksel, Ezgi Pehlivanlar Yavrucu, Hilal Zıvalı, Begüm Nurpelin Sağlık Özkan, İnci Selin Doğan   +5 more
wiley   +1 more source

Comparison of measles plaque reduction neutralization test (PRNT) and measles virus-specific IgG ELISA for assessment of immunogenicity of measles-mumps-rubella vaccination at 5-7 months of age and maternal measles antibodies. [PDF]

Vaccine X
Vittrup DM, Jensen A, Malon M, Zimakoff AC, Kiehn Sørensen J, Littell B, Simões EAF, Svensson J, Graff Stensballe L.   +8 more
europepmc   +1 more source

Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
We present a set of multifunctional tacrine derivatives, designed with the CADMA‐Chem protocol, aimed for Alzheimer and Parkinson diseases. Of the tacrines designed, TAC‐674 and TAC‐678 are the best candidates to act as multifunctional antioxidants and neuroprotectors for Alzheimer and Parkinson diseases, respectively.
Eugenia Dzib, Luis Felipe Hernández‐Ayala, Silvana Silva‐Aguirre, Annia Galano   +3 more
wiley   +1 more source

H2S‐Amplified “Three‐in‐One” Antibacterial Strategy for Periodontitis Treatment Using a Photosensitive Pillararene‐Embedded COF/MOF Hybrid

Advanced Science, Volume 13, Issue 43, 3 August 2026.
The integration of ROS‐generating systems with H2S depletion strategies effectively overcomes the limitations imposed by endogenous antioxidant defenses on ROS‐based antimicrobial therapies. In this study, the Cu‐MOF is incorporated into pillararene‐embedded COF, achieving a “three‐in‐one” antimicrobial effect that markedly alleviated periodontal ...
Shuang Liang, Meng‐Hao Li, Liang Cheng, Tian‐Shou Zhang, Hui Hui, Yan Wang, Hong‐Pu Zhang, Bo‐Wen Liu, Lin Wang, Ying‐Wei Yang   +9 more
wiley   +1 more source

A Humanized Anti‐gD Broadly Neutralizing Antibody Confers Complete Post‐Exposure Protection Against Pseudorabies Virus

Advanced Science, Volume 13, Issue 46, 17 August 2026.
Pseudorabies virus (PRV), an emerging zoonotic α‐herpesvirus, causes life‐threatening human encephalitis. We identified a broad‐spectrum neutralizing antibody 6F7 targeting PRV gD. It blocks gD‐Nectin‐1 binding and membrane fusion, inhibiting replication across all PRV variants, representing a promising candidate for anti‐PRV therapy.
Yue Sun, Jianbo Liu, Shi‐Jia Xu, Meng‐Xin Wang, Hongliang Zhang, Yanhe Zhang, Zhi‐Jun Tian, Jin‐Mei Peng, Xin Yin, Tong‐Qing An, Xue‐Hui Cai, Yan‐Dong Tang   +11 more
wiley   +1 more source

Human Leukocyte Elastase Triggered Nanoparticles for Targeted Antimicrobial Delivery and Oral Microbial Modulation

Advanced NanoBiomed Research, Volume 6, Issue 8, August 2026.
This study explores enzyme‐responsive nanoparticles for targeted antimicrobial release in inflamed oral environments. Nanoparticles formed by complexing peptides and chlorhexidine respond to human leukocyte elastase and release chlorhexidine selectively. P7 (ECAAPVCE)‐based formulations show optimal properties and stability, with antimicrobial activity
Mohammed A. Hadis, Ignacio Insua, Farah N. S. Raja, Álvaro Vila, William M. Palin, Michael R. Milward, Paul R. Cooper, Sarah A. Kuehne, Owen Addison, Paco Fernandez‐Trillo   +9 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/NgR/ROCK Signaling Pathway

CNS Neuroscience &Therapeutics, Volume 32, Issue 8, August 2026.
NAP2, a NgR1 antagonist peptide, improved cognition in APP/PS1 mice, reduced Aβ plaques and tau hyperphosphorylation, increased dendritic spine density, and alleviated mitochondrial damage, acting through inhibition of the Nogo‐A/NgR/ROCK pathway, highlighting its therapeutic potential for Alzheimer's disease.
Zheng Zhang, Huimin Tan, Fang Shi, Jiajia Dai, Weilong Ding, Junliang Li, Yuke Wang, Rui Yang, Xinke Xu, Cheng Chen, Fei Xiao, Li‐an Huang, Xiaoyan Liu, Rui Liao, Li Yan   +14 more
wiley   +1 more source

Mesenchymal stem cell‐derived exosomes for cardiac repair: Challenges, standardization gaps and a realistic path to clinical translation

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Mesenchymal stem cell‐derived exosomes (MSC‐sEVs) show preclinical promise for cardiac repair via anti‐inflammatory, anti‐apoptotic, pro‐angiogenic and anti‐fibrotic effects. However, translational hurdles remain, including non‐standardized isolation, unvalidated potency assays, incomplete GMP manufacturing, and lack of completed Phase II/III trials ...
Sakhavat Abolhasani, Yasin Ahmadi, Amin Jalizih   +2 more
wiley   +1 more source